Drug intelligence / Profile preview

FT-002a (AecorBio)

Development stage: Preclinical
Lead developer: AecorBio
Modality: Peptides
Administration: Oral

Overview

FT-002a is an orally bioavailable peptide therapeutic developed by AecorBio, designed to target Iron Responsive Element Binding Protein 2 (IREB2) and modulate the intracellular labile iron pool (LIP). By disrupting iron homeostasis, FT-002a aims to exploit the iron dependency of advanced cancer cells, particularly in castration-resistant prostate cancer (CRPC) and platinum-resistant ovarian cancer. The candidate is currently in the IND-enabling stage of development, focusing on inducing anti-tumor effects through the depletion or modulation of iron availability within the tumor microenvironment.

Targets

Iron metabolism (Iron metabolism family)

Beyond the preview

Go deeper on FT-002a (AecorBio).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT-002a (AecorBio).

Explore the full profile